Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences’ EPS trailed expectations in the second fiscal quarter of 2026, with results reported August 4, 2026 based on preliminary figures, as EPS came in at -$0.69 versus the -$0.65 estimate (difference -$0.04). Net income was a loss of roughly $45.6 million, down -62.1% year over year from a loss of about $28.1 million, while EPS declined -46.8% from -$0.47 a year ago. The company posted an operating loss of about $49.0 million as it continues development work in targeted oncology programs such as TYRA-300, and it generated negative operating cash flow of roughly $31.1 million during the quarter. For the next period, consensus calls for EPS of -$0.69.